Observation of Curative Efficacy and Prognosis following Combination Chemotherapy with Celecoxib in the Treatment of Advanced Colorectal Cancer

Abstract

This study investigated the antitumour and chemosensitizing effects of celecoxib in the treatment of advanced colorectal cancer. A total of 90 patients were randomly divided into two groups: group CF was treated with a combination of celecoxib and the folinic acid-fluorouracil-oxaliplatin (FOLFOX4) regimen; and group F was treated with the FOLFOX4 regimen alone. Immunohistochemical analysis of tumour tissues for cyclooxygenase-2 (COX-2) protein was performed. With regard to short-term efficacy, the response and disease control rates were significantly greater in group CF than group F. A log-rank test showed that the 3-year survival rate was significantly greater in group CF than group F. It was concluded that the addition of celecoxib to the FOLFOX4 regimen increased the short-term efficacy and the 3-year survival rate, and improved the quality of life of patients with advanced colorectal cancer. The antitumour and chemosensitizing effects of celecoxib appeared to be independent of COX-2.

Keywords

Celecoxib Cyclooxygenase-2 inhibitors FOLFOX4 Colorectal cancer Cyclooxygenase-2 (COX-2)Efficacy Prognosis

References

Wang

Chen

: An analysis: colon cancer mortality in Tianjin, China, from 1981 to 2000. World J Gastroenterol 2005; 11: 895–898.

Crespi

: Models of screening program for colorectal cancer. Med Arh 2002; 56 (1 suppl 1): 47–49.

Higa

: Colorectal cancer: epidemiology and primary profilaxis. Acta Gastroenterol Latinoam 2011; 41: 70–73 [in Spanish].

Cao

Prescott

: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190: 279–286.

Grkovich

Johnson

Buczynski

: Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1-dependent. J Biol Chem 2006; 281: 32978–32987.

Hirsch

Filipovich

Mahendroo

: Signaling via the type I IL-1 and TNF receptors is necessary for bacterially induced preterm labor in a murine model. Am J Obstet Gynecol 2006; 194: 1334–1340.

Tammali

Ramana

Singhal

: Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res 2006; 66: 9705–9713.

Soslow

Dannenberg

Rush

: COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 2000; 89: 2637–2645.

Brabender

Park

Metzger

: Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002; 235: 440–443.

10.

Lim

Kim

: Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol 2007; 26: 229–234.

11.

Urakawa

Nishida

Naruse

: Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: A pilot study. Clin Orthop Relat Res 2009; 467: 2932–2938.

12.

Xiao

Zhang

Lin

: Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 2008; 122: 2115–2124.

13.

Gradilone

Pulcinelli

Lotti

: Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets 2008; 8: 414–420.

14.

Zhu

Chen

Wang

: Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro. Zhonghua Zhong Liu Za Zhi 2007; 29: 186–188 [in Chinese, English abstract].

15.

Therasse

Arbuck

Eisenhauer

: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216.

16.

Owusu

Koroukian

Schluchter

: Screening older cancer patients for a Comprehensive Geriatric Assessment: A comparison of three instruments. J Geriatr Oncol 2011; 2: 121–129.

17.

Schag

Heinrich

Ganz

: Karnofsky performance status revisited: reliability, validity and guidelines. J Clin Oncol 1984; 2: 187–193.

18.

Cheng

Chan

Leung

: Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol 2004; 17: 1169–1179.

19.

Goldberg

Meropol

Tabernero

: Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. Gastrointest Cancer Res 2009; 3 (5 suppl 2): S23–S27.

20.

Waisberg

Fava

Martins

: Colonic carcinoid tumors: A clinicopathologic study of 23 patients from a single institution. Arq Gastroenterol 2009; 46: 288–293.

21.

Goldstein

Silverstein

Agrawal

: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681–1690.

22.

Johnson

Lapadat

: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911–1912.

23.

Elder

Halton

Playle

: The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002; 99: 323–327.

24.

Liu

Yao

Kirschenbaum

: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58: 4245–4249.

25.

Venkatesan

Puvvada

Dash

: The potential of celecoxib-loaded hydroxyapatite chitosan nanocomposite for the treatment of colon cancer. Biomaterials 2011; 32: 3794–3806.

26.

de Gramont

Figer

Seymour

: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–2947.

27.

Choy

Milas

: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance? J Natl Cancer Inst 2003; 95: 1440–1452.

28.

Huang

Xiao

Chen

: Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma. World J Gastroenterol 2010; 16: 5975–5981.

29.

Hyde

Missailidis

: Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol 2009; 9: 701–715.

30.

Hermanova

Karasek

Tomasek

: Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer. World J Gastroenterol 2010; 16: 1879–1884.

31.

Bertagnolli

Eagle

Zauber

: Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2009; 2: 310–321.

32.

Madan

Xia

Chang

: A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib. Expert Opin Pharmacother 2007; 8: 1425–1431.

33.

Mukherjee

Nissen

Topol

: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954–959.

34.

White

Faich

Whelton

: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425–430.

35.

Gasparini

Longo

Sarmiento

: Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents? Lancet Oncol 2003; 4: 605–615.

36.

Williams

Tsujii

Reese

: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589–1594.

37.

Shin

Park

Kim

: Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 2005; 65: 9501–9509.

38.

Palayoor

Arayankalayil

Shoaibi

: Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2. Clin Cancer Res 2005; 11: 6980–6986.

39.

Piazza

Alberts

Hixson

: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57: 2909–2915.

40.

Han

Leng

Demetris

: Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 2004; 64: 1369–1376.

41.

Grösch

Tegeder

Niederberger

: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742–2744.

42.

Maier

Schilling

Schmidt

: Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004; 67: 1469–1478.

43.

Richter

Weiss

Weinberger

: Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001; 22: 17–25.

44.

Patel

Subbaramaiah

: Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005; 11: 1999–2007.

45.

Grösch

Maier

Schiffmann

: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98: 736–747.

46.

Tang

Leung

: Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention. World J Gastroenterol 2005; 11: 41–45.

47.

Altorki

Port

Zhang

: Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 2005; 11: 4191–4197.

48.

Irie

Tsujii

Tsuji

: Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-γ. Int J Cancer 2007; 121: 878–883.